Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.74 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.74 |
| ▸ | NPC1 | O15118 | 11/20 | 0.70 |
| ▸ | RAB9A | P51151 | 10/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | AHR | P35869 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3828303 | 0.86 | NPC1 (0.71) | CSNK2A2CSNK2A1NPC1RAB9AKDM4E | |
| SCHEMBL2421423 | 0.83 | KDM4E (0.75) | CSNK2A2CSNK2A1NPC1RAB9AKDM4E | |
| SCHEMBL20522351 | 0.83 | CSNK2A2 (0.70) | CSNK2A2CSNK2A1NPC1RAB9AKDM4E | |
| SCHEMBL18788945 | 0.83 | NPC1 (0.67) | CSNK2A2CSNK2A1NPC1RAB9AKDM4E | |
| SCHEMBL14962997 | 0.82 | KDM4E (0.76) | CSNK2A2CSNK2A1NPC1RAB9AKDM4E | |
| SCHEMBL16253030 | 0.82 | NPC1 (0.64) | CSNK2A2CSNK2A1NPC1RAB9AKDM4E | |
| SCHEMBL9891908 | 0.82 | NPC1 (0.63) | CSNK2A2CSNK2A1NPC1RAB9AKDM4E | |
| SCHEMBL11480689 | 0.81 | CSNK2A2 (0.83) | CSNK2A2CSNK2A1NPC1RAB9AKDM4E | |
| SCHEMBL28568674 | 0.81 | RXFP1 (0.62) | CSNK2A2CSNK2A1NPC1RAB9AKDM4E | |
| SCHEMBL8144852 | 0.80 | RAB9A (1.00) | NPC1RAB9AKDM4ESMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889670-B2 | Heterocyclic compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CSNK2A2 1249/4885CSNK2A1 1341/4885NPC1 1779/4885 |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CSNK2A2 1420/4885CSNK2A1 1359/4885NPC1 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.